{"name":"Hanmi Pharmaceutical","slug":"hanmi","ticker":"128940.KS","exchange":"KRX","domain":"hanmi.co.kr","description":"Hanmi Pharm Co., Ltd. is a South Korean pharmaceutical company that is headquartered in Seoul.","hq":"Seoul, South Korea","founded":1990,"employees":"~1,500","ceo":"Kwan Sun Lee","sector":"Diabetes / Obesity / Branded Generics","stockPrice":493500,"stockChange":-13500,"stockChangePercent":-2.66,"marketCap":"$6.3T","metrics":{"revenue":1547531059200,"revenueGrowth":23.1,"grossMargin":57.1,"rdSpend":0,"netIncome":169554329600,"cash":201322201088,"dividendYield":0.39,"peRatio":27.9,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2028-06-01","label":"sitagliptin patent cliff ($1.2B at risk)","drug":"sitagliptin","type":"patent_expiry","sentiment":"negative"},{"date":"2030-06-01","label":"vildagliptin patent cliff ($500M at risk)","drug":"vildagliptin","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":42,"colorKey":"cardiovascular","drugs":[{"name":"HCP1202","genericName":"HCP1202","slug":"hcp1202","indication":"Type 2 diabetes mellitus","status":"phase_3"},{"name":"HGP1011","genericName":"HGP1011","slug":"hgp1011","indication":"Type 2 diabetes mellitus","status":"phase_3"},{"name":"HGP1705","genericName":"HGP1705","slug":"hgp1705","indication":"Type 2 diabetes mellitus","status":"phase_3"},{"name":"HGP1805","genericName":"HGP1805","slug":"hgp1805","indication":"Type 2 diabetes mellitus","status":"phase_3"},{"name":"HGP1909","genericName":"HGP1909","slug":"hgp1909","indication":"Type 2 diabetes mellitus","status":"phase_3"},{"name":"HGP1911","genericName":"HGP1911","slug":"hgp1911","indication":"Type 2 diabetes mellitus","status":"phase_3"},{"name":"HGP2102-1","genericName":"HGP2102-1","slug":"hgp2102-1","indication":"Type 2 diabetes mellitus","status":"phase_3"},{"name":"HGP2102-2","genericName":"HGP2102-2","slug":"hgp2102-2","indication":"Type 2 diabetes mellitus","status":"phase_3"},{"name":"HIP1601","genericName":"HIP1601","slug":"hip1601","indication":"Type 2 diabetes mellitus","status":"phase_3"},{"name":"HPP2002-1","genericName":"HPP2002-1","slug":"hpp2002-1","indication":"Type 2 diabetes mellitus","status":"phase_3"},{"name":"HPP2101","genericName":"HPP2101","slug":"hpp2101","indication":"Type 2 diabetes mellitus","status":"phase_3"},{"name":"HPP2102","genericName":"HPP2102","slug":"hpp2102","indication":"Type 2 diabetes mellitus","status":"phase_3"},{"name":"HPP2103-2","genericName":"HPP2103-2","slug":"hpp2103-2","indication":"Type 2 diabetes mellitus","status":"phase_3"},{"name":"HPP2201","genericName":"HPP2201","slug":"hpp2201","indication":"Type 2 diabetes mellitus","status":"phase_3"},{"name":"RLD2101","genericName":"RLD2101","slug":"rld2101","indication":"Type 2 diabetes","status":"phase_3"},{"name":"RLD2106-2","genericName":"RLD2106-2","slug":"rld2106-2","indication":"Type 2 diabetes","status":"phase_3"},{"name":"HCP1102Placebo+HGP0711","genericName":"HCP1102Placebo+HGP0711","slug":"hcp1102placebo-hgp0711","indication":"Type 2 diabetes mellitus","status":"phase_3"},{"name":"HCP1302","genericName":"HCP1302","slug":"hcp1302","indication":"Type 2 diabetes mellitus","status":"phase_3"},{"name":"HCP1401","genericName":"HCP1401","slug":"hcp1401","indication":"Type 2 diabetes mellitus","status":"phase_3"},{"name":"HCP1701","genericName":"HCP1701","slug":"hcp1701","indication":"Type 2 diabetes mellitus","status":"phase_3"},{"name":"HCP1803-3","genericName":"HCP1803-3","slug":"hcp1803-3","indication":"Type 2 diabetes mellitus","status":"phase_3"},{"name":"HCP1904-2","genericName":"HCP1904-2","slug":"hcp1904-2","indication":"Type 2 diabetes mellitus","status":"phase_3"},{"name":"HCP1904-3","genericName":"HCP1904-3","slug":"hcp1904-3","indication":"Type 2 diabetes mellitus","status":"phase_3"},{"name":"HCP2102-1","genericName":"HCP2102-1","slug":"hcp2102-1","indication":"Type 2 diabetes mellitus","status":"phase_3"},{"name":"HCP2102-2","genericName":"HCP2102-2","slug":"hcp2102-2","indication":"Type 2 diabetes mellitus","status":"phase_3"},{"name":"HGP1201","genericName":"HGP1201","slug":"hgp1201","indication":"Type 2 diabetes mellitus","status":"phase_3"},{"name":"HGP1910","genericName":"HGP1910","slug":"hgp1910","indication":"Type 2 diabetes mellitus","status":"phase_3"},{"name":"HIP1402","genericName":"HIP1402","slug":"hip1402","indication":"Type 2 diabetes mellitus","status":"phase_3"},{"name":"HPP2003-3","genericName":"HPP2003-3","slug":"hpp2003-3","indication":"Type 2 diabetes mellitus","status":"phase_3"},{"name":"HPP2004","genericName":"HPP2004","slug":"hpp2004","indication":"Type 2 diabetes mellitus","status":"phase_3"},{"name":"HPP2103-1","genericName":"HPP2103-1","slug":"hpp2103-1","indication":"Type 2 diabetes mellitus","status":"phase_3"},{"name":"HPP2104-1","genericName":"HPP2104-1","slug":"hpp2104-1","indication":"Type 2 diabetes mellitus","status":"phase_3"},{"name":"HPP2104-2","genericName":"HPP2104-2","slug":"hpp2104-2","indication":"Type 2 diabetes mellitus","status":"phase_3"},{"name":"HPP2202","genericName":"HPP2202","slug":"hpp2202","indication":"Type 2 diabetes mellitus","status":"phase_3"},{"name":"RLD2001-1","genericName":"RLD2001-1","slug":"rld2001-1","indication":"Type 2 diabetes","status":"phase_3"},{"name":"RLD2001-2","genericName":"RLD2001-2","slug":"rld2001-2","indication":"Type 2 diabetes","status":"phase_3"},{"name":"RLD2002","genericName":"RLD2002","slug":"rld2002","indication":"Type 2 diabetes","status":"phase_3"},{"name":"RLD2106-1","genericName":"RLD2106-1","slug":"rld2106-1","indication":"Type 2 diabetes","status":"phase_3"},{"name":"RLD2209-1","genericName":"RLD2209-1","slug":"rld2209-1","indication":"Type 2 diabetes","status":"phase_3"},{"name":"RLD2209-2","genericName":"RLD2209-2","slug":"rld2209-2","indication":"Type 2 diabetes","status":"phase_3"},{"name":"RLD2401","genericName":"RLD2401","slug":"rld2401","indication":"Type 2 diabetes","status":"phase_3"},{"name":"Victoza","genericName":"Victoza","slug":"victoza","indication":"Diabetes mellitus type 2","status":"marketed"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":30,"colorKey":"oncology","drugs":[{"name":"Cavir","genericName":"Cavir","slug":"cavir","indication":"Other","status":"marketed"},{"name":"HCP1903","genericName":"HCP1903","slug":"hcp1903","indication":"Other","status":"phase_3"},{"name":"HGP0608","genericName":"HGP0608","slug":"hgp0608","indication":"Muscle wasting or sarcopenia","status":"phase_3"},{"name":"HIP1801","genericName":"HIP1801","slug":"hip1801","indication":"Other","status":"phase_1"},{"name":"current treatment","genericName":"current treatment","slug":"current-treatment","indication":"Other","status":"marketed"},{"name":"Amlodipine, Losartan","genericName":"Amlodipine, Losartan","slug":"amlodipine-losartan","indication":"Other","status":"marketed"},{"name":"Amosartan Plus Tab.","genericName":"Amosartan Plus Tab.","slug":"amosartan-plus-tab","indication":"Other","status":"phase_2"},{"name":"Amosartan Q tablet","genericName":"Amosartan Q tablet","slug":"amosartan-q-tablet","indication":"Other","status":"phase_2"},{"name":"Atorvastatin A","genericName":"Atorvastatin A","slug":"atorvastatin-a","indication":"Other","status":"marketed"},{"name":"Atorvastatin B","genericName":"Atorvastatin B","slug":"atorvastatin-b","indication":"Other","status":"marketed"},{"name":"BH3120","genericName":"BH3120","slug":"bh3120","indication":"Other","status":"phase_1"},{"name":"Esomezol Cap","genericName":"Esomezol Cap","slug":"esomezol-cap","indication":"Other","status":"phase_2"},{"name":"HCP1201, Fasted followed by fed","genericName":"HCP1201, Fasted followed by fed","slug":"hcp1201-fasted-followed-by-fed","indication":"Other","status":"phase_1"},{"name":"HGP0919","genericName":"HGP0919","slug":"hgp0919","indication":"Other","status":"phase_1"},{"name":"HIP1601 40mg","genericName":"HIP1601 40mg","slug":"hip1601-40mg","indication":"Other","status":"phase_1"},{"name":"HM10560A","genericName":"HM10560A","slug":"hm10560a","indication":"Other","status":"phase_2"},{"name":"HM10660A","genericName":"HM10660A","slug":"hm10660a","indication":"Other","status":"phase_1"},{"name":"HM15136","genericName":"HM15136","slug":"hm15136","indication":"Other","status":"phase_2"},{"name":"HM71224 Multiple ascending dose","genericName":"HM71224 Multiple ascending dose","slug":"hm71224-multiple-ascending-dose","indication":"Other","status":"phase_1"},{"name":"HM95573, cobimetinib","genericName":"HM95573, cobimetinib","slug":"hm95573-cobimetinib","indication":"Other","status":"phase_1"},{"name":"Placebo (for HCP1302)","genericName":"Placebo (for HCP1302)","slug":"placebo-for-hcp1302","indication":"Other","status":"phase_3"},{"name":"Placebo (for HGP0904)","genericName":"Placebo (for HGP0904)","slug":"placebo-for-hgp0904","indication":"Other","status":"phase_3"},{"name":"Placebo of HCP1105","genericName":"Placebo of HCP1105","slug":"placebo-of-hcp1105","indication":"Other","status":"phase_3"},{"name":"Placebo of HGP0816","genericName":"Placebo of HGP0816","slug":"placebo-of-hgp0816","indication":"Other","status":"phase_3"},{"name":"Pseudoephedrine / Levocetirizine","genericName":"Pseudoephedrine / Levocetirizine","slug":"pseudoephedrine-levocetirizine","indication":"Allergic rhinitis with nasal congestion","status":"phase_3"},{"name":"RLD2204","genericName":"RLD2204","slug":"rld2204","indication":"Other","status":"phase_3"},{"name":"Traclear","genericName":"Traclear","slug":"traclear","indication":"Other","status":"phase_1"},{"name":"Zocor","genericName":"Zocor","slug":"zocor","indication":"Other","status":"marketed"},{"name":"one-way education","genericName":"one-way education","slug":"one-way-education","indication":"Other","status":"marketed"},{"name":"two-way education","genericName":"two-way education","slug":"two-way-education","indication":"Other","status":"marketed"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":14,"colorKey":"immunology","drugs":[{"name":"HCP1004","genericName":"HCP1004","slug":"hcp1004","indication":"Castration-resistant prostate cancer (CRPC)","status":"phase_3"},{"name":"HM15211","genericName":"HM15211","slug":"hm15211","indication":"Advanced solid tumors (Phase 2 development)","status":"phase_2"},{"name":"HCP0605","genericName":"HCP0605","slug":"hcp0605","indication":"Castration-resistant prostate cancer (CRPC)","status":"phase_3"},{"name":"HCP0910","genericName":"HCP0910","slug":"hcp0910","indication":"Castration-resistant prostate cancer (CRPC)","status":"phase_3"},{"name":"HCP1102","genericName":"HCP1102","slug":"hcp1102","indication":"Castration-resistant prostate cancer (CRPC)","status":"phase_3"},{"name":"HCP1105","genericName":"HCP1105","slug":"hcp1105","indication":"Castration-resistant prostate cancer (CRPC)","status":"phase_3"},{"name":"HCP1904-1","genericName":"HCP1904-1","slug":"hcp1904-1","indication":"Castration-resistant prostate cancer (CRPC)","status":"phase_3"},{"name":"HGP0412 capsule","genericName":"HGP0412 capsule","slug":"hgp0412-capsule","indication":"FGFR-altered solid tumors (Phase 3 development)","status":"phase_3"},{"name":"HGP0816","genericName":"HGP0816","slug":"hgp0816","indication":"Castration-resistant prostate cancer (CRPC)","status":"phase_3"},{"name":"HGP0904","genericName":"HGP0904","slug":"hgp0904","indication":"Estrogen receptor-positive, HER2-negative advanced or metastatic breast cancer","status":"phase_3"},{"name":"HGP1408","genericName":"HGP1408","slug":"hgp1408","indication":"Castration-resistant prostate cancer (CRPC)","status":"phase_3"},{"name":"HIP0612","genericName":"HIP0612","slug":"hip0612","indication":"FGFR-altered gastric cancer","status":"phase_3"},{"name":"HIP2101","genericName":"HIP2101","slug":"hip2101","indication":"Peripheral T-cell lymphoma (PTCL)","status":"phase_3"},{"name":"HM11260C","genericName":"HM11260C","slug":"hm11260c","indication":"Hormone receptor-positive, HER2-negative breast cancer","status":"phase_3"}]},{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":8,"colorKey":"neuroscience","drugs":[{"name":"Rosuvastatin and Ezetimibe","genericName":"Rosuvastatin and Ezetimibe","slug":"rosuvastatin-and-ezetimibe","indication":"Hypercholesterolemia and dyslipidemia","status":"marketed"},{"name":"Amlodipine plus Losartan","genericName":"Amlodipine plus Losartan","slug":"amlodipine-plus-losartan","indication":"Hypertension","status":"phase_3"},{"name":"Amlodipine/Losartan/Chlorthalidone","genericName":"Amlodipine/Losartan/Chlorthalidone","slug":"amlodipine-losartan-chlorthalidone","indication":"Hypertension (marketed combination therapy)","status":"marketed"},{"name":"Amosartan® tab","genericName":"Amosartan® tab","slug":"amosartan-tab","indication":"Hypertension","status":"marketed"},{"name":"Cozaar® plus pro tab","genericName":"Cozaar® plus pro tab","slug":"cozaar-plus-pro-tab","indication":"Hypertension","status":"marketed"},{"name":"Irbesartan/Atorvastatin A","genericName":"Irbesartan/Atorvastatin A","slug":"irbesartan-atorvastatin-a","indication":"Hypertension with dyslipidemia","status":"phase_3"},{"name":"Irbesartan/Atorvastatin B","genericName":"Irbesartan/Atorvastatin B","slug":"irbesartan-atorvastatin-b","indication":"Hypertension with dyslipidemia","status":"phase_3"},{"name":"Simvast CR","genericName":"Simvast CR","slug":"simvast-cr","indication":"Hypercholesterolemia and dyslipidemia","status":"marketed"}]},{"name":"Respiratory","slug":"respiratory","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"infectious","drugs":[{"name":"Montelukast + Levocetirizine","genericName":"Montelukast + Levocetirizine","slug":"montelukast-levocetirizine","indication":"Allergic rhinitis","status":"phase_3"}]}],"pipeline":[{"name":"Cavir","genericName":"Cavir","slug":"cavir","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"HCP1004","genericName":"HCP1004","slug":"hcp1004","phase":"phase_3","mechanism":"HCP1004 is a selective androgen receptor degrader (SARD) that binds to and promotes degradation of the androgen receptor protein.","indications":["Castration-resistant prostate cancer (CRPC)"],"catalyst":""},{"name":"HCP1202","genericName":"HCP1202","slug":"hcp1202","phase":"phase_3","mechanism":"HCP1202 is a dual GLP-1/GIP receptor agonist that activates both glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide receptors to improve glycemic control and promote weight loss.","indications":["Type 2 diabetes mellitus"],"catalyst":""},{"name":"HCP1903","genericName":"HCP1903","slug":"hcp1903","phase":"phase_3","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"HGP0608","genericName":"HGP0608","slug":"hgp0608","phase":"phase_3","mechanism":"HGP0608 is a selective androgen receptor modulator (SARM) that binds to androgen receptors to promote anabolic effects while minimizing androgenic side effects.","indications":["Muscle wasting or sarcopenia","Bone health / osteoporosis"],"catalyst":""},{"name":"HGP1011","genericName":"HGP1011","slug":"hgp1011","phase":"phase_3","mechanism":"HGP1011 is a long-acting GLP-1 receptor agonist that enhances insulin secretion and reduces glucagon levels to improve glycemic control in diabetes.","indications":["Type 2 diabetes mellitus"],"catalyst":""},{"name":"HGP1705","genericName":"HGP1705","slug":"hgp1705","phase":"phase_3","mechanism":"HGP1705 is a long-acting GLP-1 receptor agonist that enhances insulin secretion and reduces glucagon levels to improve glycemic control in diabetes.","indications":["Type 2 diabetes mellitus"],"catalyst":""},{"name":"HGP1805","genericName":"HGP1805","slug":"hgp1805","phase":"phase_3","mechanism":"HGP1805 is a long-acting GLP-1 receptor agonist that enhances insulin secretion and reduces glucagon levels to improve glycemic control in diabetes.","indications":["Type 2 diabetes mellitus"],"catalyst":""},{"name":"HGP1909","genericName":"HGP1909","slug":"hgp1909","phase":"phase_3","mechanism":"HGP1909 is a long-acting GLP-1 receptor agonist that enhances insulin secretion and reduces glucagon levels to improve glycemic control in diabetes.","indications":["Type 2 diabetes mellitus"],"catalyst":""},{"name":"HGP1911","genericName":"HGP1911","slug":"hgp1911","phase":"phase_3","mechanism":"HGP1911 is a long-acting GLP-1 receptor agonist that enhances insulin secretion and reduces glucagon levels to improve glycemic control in diabetes.","indications":["Type 2 diabetes mellitus"],"catalyst":""},{"name":"HGP2102-1","genericName":"HGP2102-1","slug":"hgp2102-1","phase":"phase_3","mechanism":"HGP2102-1 is a long-acting GLP-1 receptor agonist designed to improve glycemic control in diabetes by enhancing insulin secretion and reducing glucagon release.","indications":["Type 2 diabetes mellitus"],"catalyst":""},{"name":"HGP2102-2","genericName":"HGP2102-2","slug":"hgp2102-2","phase":"phase_3","mechanism":"HGP2102-2 is a long-acting GLP-1 receptor agonist designed to improve glycemic control in diabetes by enhancing insulin secretion and reducing glucagon release.","indications":["Type 2 diabetes mellitus"],"catalyst":""},{"name":"HIP1601","genericName":"HIP1601","slug":"hip1601","phase":"phase_3","mechanism":"HIP1601 is a long-acting GLP-1 receptor agonist that enhances insulin secretion and reduces glucagon levels to improve glycemic control in diabetes.","indications":["Type 2 diabetes mellitus"],"catalyst":""},{"name":"HIP1801","genericName":"HIP1801","slug":"hip1801","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"HM15211","genericName":"HM15211","slug":"hm15211","phase":"phase_2","mechanism":"HM15211 is a bispecific antibody that simultaneously engages two distinct immune checkpoints to enhance anti-tumor T cell responses.","indications":["Advanced solid tumors (Phase 2 development)"],"catalyst":""},{"name":"HPP2002-1","genericName":"HPP2002-1","slug":"hpp2002-1","phase":"phase_3","mechanism":"HPP2002-1 is a long-acting GLP-1 receptor agonist designed to improve glycemic control and promote weight loss in metabolic disorders.","indications":["Type 2 diabetes mellitus","Obesity or weight management"],"catalyst":""},{"name":"HPP2101","genericName":"HPP2101","slug":"hpp2101","phase":"phase_3","mechanism":"HPP2101 is a long-acting GLP-1 receptor agonist designed to improve glycemic control and promote weight loss in metabolic disorders.","indications":["Type 2 diabetes mellitus"],"catalyst":""},{"name":"HPP2102","genericName":"HPP2102","slug":"hpp2102","phase":"phase_3","mechanism":"HPP2102 is a long-acting GLP-1 receptor agonist designed to improve glycemic control and promote weight loss in metabolic disorders.","indications":["Type 2 diabetes mellitus","Obesity or weight management"],"catalyst":""},{"name":"HPP2103-2","genericName":"HPP2103-2","slug":"hpp2103-2","phase":"phase_3","mechanism":"HPP2103-2 is a long-acting GLP-1 receptor agonist designed to improve glycemic control in diabetes by enhancing insulin secretion and reducing glucagon release.","indications":["Type 2 diabetes mellitus"],"catalyst":""},{"name":"HPP2201","genericName":"HPP2201","slug":"hpp2201","phase":"phase_3","mechanism":"HPP2201 is a long-acting GLP-1 receptor agonist designed to improve glycemic control and promote weight loss in metabolic disorders.","indications":["Type 2 diabetes mellitus","Obesity or weight management"],"catalyst":""},{"name":"RLD2101","genericName":"RLD2101","slug":"rld2101","phase":"phase_3","mechanism":"RLD2101 is a small molecule that targets the SGLT2 receptor.","indications":["Type 2 diabetes"],"catalyst":""},{"name":"RLD2106-2","genericName":"RLD2106-2","slug":"rld2106-2","phase":"phase_3","mechanism":"RLD2106-2 is a small molecule that targets the SGLT2 receptor.","indications":["Type 2 diabetes"],"catalyst":""},{"name":"Rosuvastatin and Ezetimibe","genericName":"Rosuvastatin and Ezetimibe","slug":"rosuvastatin-and-ezetimibe","phase":"marketed","mechanism":"Rosuvastatin inhibits HMG-CoA reductase to lower LDL cholesterol, while ezetimibe blocks intestinal cholesterol absorption, providing dual lipid-lowering action.","indications":["Hypercholesterolemia and dyslipidemia","Cardiovascular risk reduction in patients requiring additional LDL-C lowering"],"catalyst":""},{"name":"current treatment","genericName":"current treatment","slug":"current-treatment","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Amlodipine plus Losartan","genericName":"Amlodipine plus Losartan","slug":"amlodipine-plus-losartan","phase":"phase_3","mechanism":"Amlodipine and losartan work together to lower blood pressure by relaxing blood vessels through calcium channel blockade and angiotensin II receptor antagonism.","indications":["Hypertension"],"catalyst":""},{"name":"Amlodipine, Losartan","genericName":"Amlodipine, Losartan","slug":"amlodipine-losartan","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Amlodipine/Losartan/Chlorthalidone","genericName":"Amlodipine/Losartan/Chlorthalidone","slug":"amlodipine-losartan-chlorthalidone","phase":"marketed","mechanism":"This triple-combination antihypertensive reduces blood pressure through three complementary mechanisms: calcium channel blockade, angiotensin II receptor antagonism, and thiazide diuresis.","indications":["Hypertension (marketed combination therapy)"],"catalyst":""},{"name":"Amosartan Plus Tab.","genericName":"Amosartan Plus Tab.","slug":"amosartan-plus-tab","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Amosartan Q tablet","genericName":"Amosartan Q tablet","slug":"amosartan-q-tablet","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Amosartan® tab","genericName":"Amosartan® tab","slug":"amosartan-tab","phase":"marketed","mechanism":"Amosartan is an angiotensin II receptor blocker (ARB) that selectively antagonizes the AT1 receptor to reduce vasoconstriction and lower blood pressure.","indications":["Hypertension","Diabetic nephropathy (in some markets)"],"catalyst":""},{"name":"Atorvastatin A","genericName":"Atorvastatin A","slug":"atorvastatin-a","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Atorvastatin B","genericName":"Atorvastatin B","slug":"atorvastatin-b","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"BH3120","genericName":"BH3120","slug":"bh3120","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Cozaar® plus pro tab","genericName":"Cozaar® plus pro tab","slug":"cozaar-plus-pro-tab","phase":"marketed","mechanism":"Cozaar (losartan) blocks angiotensin II receptors to relax blood vessels and lower blood pressure.","indications":["Hypertension","Diabetic nephropathy in patients with type 2 diabetes","Reduction of cardiovascular risk in hypertensive patients"],"catalyst":""},{"name":"Esomezol Cap","genericName":"Esomezol Cap","slug":"esomezol-cap","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"HCP0605","genericName":"HCP0605","slug":"hcp0605","phase":"phase_3","mechanism":"HCP0605 is a selective androgen receptor degrader (SARD) that binds to and promotes degradation of the androgen receptor protein.","indications":["Castration-resistant prostate cancer (CRPC)","Androgen receptor-positive breast cancer"],"catalyst":""},{"name":"HCP0910","genericName":"HCP0910","slug":"hcp0910","phase":"phase_3","mechanism":"HCP0910 is a selective androgen receptor degrader (SARD) that binds to and promotes degradation of the androgen receptor protein.","indications":["Castration-resistant prostate cancer (CRPC)","Hormone-sensitive prostate cancer"],"catalyst":""},{"name":"HCP1102","genericName":"HCP1102","slug":"hcp1102","phase":"phase_3","mechanism":"HCP1102 is a selective androgen receptor degrader (SARD) that binds to and promotes degradation of the androgen receptor protein.","indications":["Castration-resistant prostate cancer (CRPC)"],"catalyst":""},{"name":"HCP1102Placebo+HGP0711","genericName":"HCP1102Placebo+HGP0711","slug":"hcp1102placebo-hgp0711","phase":"phase_3","mechanism":"HCP1102 is a dual GLP-1/GIP receptor agonist combined with HGP0711 (a GLP-1 receptor agonist) to enhance glucose control and weight loss through incretin mimicry.","indications":["Type 2 diabetes mellitus"],"catalyst":""},{"name":"HCP1105","genericName":"HCP1105","slug":"hcp1105","phase":"phase_3","mechanism":"HCP1105 is a selective androgen receptor degrader (SARD) that binds to and promotes degradation of the androgen receptor protein.","indications":["Castration-resistant prostate cancer (CRPC)","Metastatic castration-resistant prostate cancer (mCRPC)"],"catalyst":""},{"name":"HCP1201, Fasted followed by fed","genericName":"HCP1201, Fasted followed by fed","slug":"hcp1201-fasted-followed-by-fed","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"HCP1302","genericName":"HCP1302","slug":"hcp1302","phase":"phase_3","mechanism":"HCP1302 is a long-acting GLP-1 receptor agonist that enhances insulin secretion and reduces glucagon levels to improve glycemic control in diabetes.","indications":["Type 2 diabetes mellitus"],"catalyst":""},{"name":"HCP1401","genericName":"HCP1401","slug":"hcp1401","phase":"phase_3","mechanism":"HCP1401 is a long-acting GLP-1 receptor agonist that enhances insulin secretion and reduces glucagon levels to improve glycemic control in diabetes.","indications":["Type 2 diabetes mellitus"],"catalyst":""},{"name":"HCP1701","genericName":"HCP1701","slug":"hcp1701","phase":"phase_3","mechanism":"HCP1701 is a long-acting GLP-1 receptor agonist that enhances insulin secretion and reduces glucagon levels to improve glycemic control in diabetes.","indications":["Type 2 diabetes mellitus"],"catalyst":""},{"name":"HCP1803-3","genericName":"HCP1803-3","slug":"hcp1803-3","phase":"phase_3","mechanism":"HCP1803-3 is a long-acting GLP-1 receptor agonist designed to improve glycemic control and promote weight loss in metabolic disorders.","indications":["Type 2 diabetes mellitus","Obesity or weight management"],"catalyst":""},{"name":"HCP1904-1","genericName":"HCP1904-1","slug":"hcp1904-1","phase":"phase_3","mechanism":"HCP1904-1 is a selective androgen receptor degrader (SARD) that binds to and promotes degradation of the androgen receptor protein.","indications":["Castration-resistant prostate cancer (CRPC)","Hormone-sensitive prostate cancer"],"catalyst":""},{"name":"HCP1904-2","genericName":"HCP1904-2","slug":"hcp1904-2","phase":"phase_3","mechanism":"HCP1904-2 is a long-acting GLP-1 receptor agonist designed to improve glycemic control in diabetes by enhancing insulin secretion and reducing glucagon release.","indications":["Type 2 diabetes mellitus"],"catalyst":""},{"name":"HCP1904-3","genericName":"HCP1904-3","slug":"hcp1904-3","phase":"phase_3","mechanism":"HCP1904-3 is a long-acting GLP-1 receptor agonist designed to improve glycemic control in diabetes by enhancing insulin secretion and reducing glucagon release.","indications":["Type 2 diabetes mellitus"],"catalyst":""},{"name":"HCP2102-1","genericName":"HCP2102-1","slug":"hcp2102-1","phase":"phase_3","mechanism":"HCP2102-1 is a long-acting GLP-1 receptor agonist designed to improve glycemic control and promote weight loss in metabolic disorders.","indications":["Type 2 diabetes mellitus","Obesity or weight management"],"catalyst":""},{"name":"HCP2102-2","genericName":"HCP2102-2","slug":"hcp2102-2","phase":"phase_3","mechanism":"HCP2102-2 is a long-acting GLP-1 receptor agonist designed to improve glycemic control and promote weight loss in metabolic disorders.","indications":["Type 2 diabetes mellitus","Obesity or weight management"],"catalyst":""},{"name":"HGP0412 capsule","genericName":"HGP0412 capsule","slug":"hgp0412-capsule","phase":"phase_3","mechanism":"HGP0412 is a selective inhibitor of fibroblast growth factor receptor (FGFR) that blocks aberrant FGFR signaling in cancer cells.","indications":["FGFR-altered solid tumors (Phase 3 development)"],"catalyst":""},{"name":"HGP0816","genericName":"HGP0816","slug":"hgp0816","phase":"phase_3","mechanism":"HGP0816 is a selective androgen receptor degrader (SARD) that binds to and promotes degradation of the androgen receptor protein.","indications":["Castration-resistant prostate cancer (CRPC)"],"catalyst":""},{"name":"HGP0904","genericName":"HGP0904","slug":"hgp0904","phase":"phase_3","mechanism":"HGP0904 is a selective estrogen receptor degrader (SERD) that binds to and degrades estrogen receptors, blocking estrogen-dependent signaling in hormone-sensitive cancers.","indications":["Estrogen receptor-positive, HER2-negative advanced or metastatic breast cancer"],"catalyst":""},{"name":"HGP0919","genericName":"HGP0919","slug":"hgp0919","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"HGP1201","genericName":"HGP1201","slug":"hgp1201","phase":"phase_3","mechanism":"HGP1201 is a long-acting GLP-1 receptor agonist that enhances insulin secretion and reduces glucagon levels to improve glycemic control in diabetes.","indications":["Type 2 diabetes mellitus"],"catalyst":""},{"name":"HGP1408","genericName":"HGP1408","slug":"hgp1408","phase":"phase_3","mechanism":"HGP1408 is a selective androgen receptor degrader (SARD) that binds to and degrades the androgen receptor protein, eliminating both its transcriptional activity and protein expression.","indications":["Castration-resistant prostate cancer (CRPC)","Hormone-sensitive prostate cancer"],"catalyst":""},{"name":"HGP1910","genericName":"HGP1910","slug":"hgp1910","phase":"phase_3","mechanism":"HGP1910 is a long-acting GLP-1 receptor agonist that enhances insulin secretion and reduces glucagon levels to improve glycemic control in diabetes.","indications":["Type 2 diabetes mellitus"],"catalyst":""},{"name":"HIP0612","genericName":"HIP0612","slug":"hip0612","phase":"phase_3","mechanism":"HIP0612 is a selective inhibitor of fibroblast growth factor receptor (FGFR) that blocks aberrant FGFR signaling in cancer cells.","indications":["FGFR-altered gastric cancer","FGFR-altered urothelial cancer"],"catalyst":""},{"name":"HIP1402","genericName":"HIP1402","slug":"hip1402","phase":"phase_3","mechanism":"HIP1402 is a long-acting GLP-1 receptor agonist that enhances insulin secretion and reduces glucagon levels to improve glycemic control in diabetes.","indications":["Type 2 diabetes mellitus"],"catalyst":""},{"name":"HIP1601 40mg","genericName":"HIP1601 40mg","slug":"hip1601-40mg","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"HIP2101","genericName":"HIP2101","slug":"hip2101","phase":"phase_3","mechanism":"HIP2101 is a selective inhibitor of histone deacetylase (HDAC) that promotes acetylation of histone and non-histone proteins to modulate gene expression and induce anti-tumor effects.","indications":["Peripheral T-cell lymphoma (PTCL)","Cutaneous T-cell lymphoma (CTCL)"],"catalyst":""},{"name":"HM10560A","genericName":"HM10560A","slug":"hm10560a","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"HM10660A","genericName":"HM10660A","slug":"hm10660a","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"HM11260C","genericName":"HM11260C","slug":"hm11260c","phase":"phase_3","mechanism":"HM11260C is a selective estrogen receptor degrader (SERD) that binds to and degrades estrogen receptors, blocking estrogen-dependent signaling in hormone-sensitive cancers.","indications":["Hormone receptor-positive, HER2-negative breast cancer"],"catalyst":""},{"name":"HM15136","genericName":"HM15136","slug":"hm15136","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"HM71224 Multiple ascending dose","genericName":"HM71224 Multiple ascending dose","slug":"hm71224-multiple-ascending-dose","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"HM95573, cobimetinib","genericName":"HM95573, cobimetinib","slug":"hm95573-cobimetinib","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"HPP2003-3","genericName":"HPP2003-3","slug":"hpp2003-3","phase":"phase_3","mechanism":"HPP2003-3 is a long-acting GLP-1 receptor agonist designed to improve glycemic control in diabetes by enhancing insulin secretion and reducing glucagon release.","indications":["Type 2 diabetes mellitus"],"catalyst":""},{"name":"HPP2004","genericName":"HPP2004","slug":"hpp2004","phase":"phase_3","mechanism":"HPP2004 is a long-acting GLP-1 receptor agonist that enhances insulin secretion and reduces glucagon levels to improve glycemic control in diabetes.","indications":["Type 2 diabetes mellitus"],"catalyst":""},{"name":"HPP2103-1","genericName":"HPP2103-1","slug":"hpp2103-1","phase":"phase_3","mechanism":"HPP2103-1 is a long-acting GLP-1 receptor agonist designed to improve glycemic control in diabetes by enhancing insulin secretion and reducing glucagon release.","indications":["Type 2 diabetes mellitus"],"catalyst":""},{"name":"HPP2104-1","genericName":"HPP2104-1","slug":"hpp2104-1","phase":"phase_3","mechanism":"HPP2104-1 is a long-acting GLP-1 receptor agonist designed to improve glycemic control in diabetes by enhancing insulin secretion and reducing glucagon release.","indications":["Type 2 diabetes mellitus"],"catalyst":""},{"name":"HPP2104-2","genericName":"HPP2104-2","slug":"hpp2104-2","phase":"phase_3","mechanism":"HPP2104-2 is a long-acting GLP-1 receptor agonist designed to improve glycemic control and promote weight loss in metabolic disorders.","indications":["Type 2 diabetes mellitus"],"catalyst":""},{"name":"HPP2202","genericName":"HPP2202","slug":"hpp2202","phase":"phase_3","mechanism":"HPP2202 is a long-acting GLP-1 receptor agonist that enhances insulin secretion and reduces glucagon levels to improve glycemic control in diabetes.","indications":["Type 2 diabetes mellitus"],"catalyst":""},{"name":"Irbesartan/Atorvastatin A","genericName":"Irbesartan/Atorvastatin A","slug":"irbesartan-atorvastatin-a","phase":"phase_3","mechanism":"Irbesartan/Atorvastatin is a fixed-dose combination that lowers blood pressure via angiotensin II receptor blockade and reduces cholesterol via HMG-CoA reductase inhibition.","indications":["Hypertension with dyslipidemia","Cardiovascular risk reduction in patients requiring both antihypertensive and lipid-lowering therapy"],"catalyst":""},{"name":"Irbesartan/Atorvastatin B","genericName":"Irbesartan/Atorvastatin B","slug":"irbesartan-atorvastatin-b","phase":"phase_3","mechanism":"Irbesartan/Atorvastatin B is a fixed-dose combination that lowers blood pressure via angiotensin II receptor blockade and reduces cholesterol via HMG-CoA reductase inhibition.","indications":["Hypertension with dyslipidemia","Cardiovascular risk reduction in patients requiring both antihypertensive and lipid-lowering therapy"],"catalyst":""},{"name":"Montelukast + Levocetirizine","genericName":"Montelukast + Levocetirizine","slug":"montelukast-levocetirizine","phase":"phase_3","mechanism":"This combination blocks cysteinyl leukotriene receptors (montelukast) and histamine H1 receptors (levocetirizine) to reduce allergic inflammation and symptoms.","indications":["Allergic rhinitis","Asthma (allergic component)","Allergic conditions with combined leukotriene and histamine involvement"],"catalyst":""},{"name":"Placebo (for HCP1302)","genericName":"Placebo (for HCP1302)","slug":"placebo-for-hcp1302","phase":"phase_3","mechanism":"Placebo has no active pharmacological mechanism and serves as a control comparator in clinical trials.","indications":[],"catalyst":""},{"name":"Placebo (for HGP0904)","genericName":"Placebo (for HGP0904)","slug":"placebo-for-hgp0904","phase":"phase_3","mechanism":"Placebo is an inert substance with no active pharmacological mechanism.","indications":[],"catalyst":""},{"name":"Placebo of HCP1105","genericName":"Placebo of HCP1105","slug":"placebo-of-hcp1105","phase":"phase_3","mechanism":"This is a placebo control and contains no active pharmaceutical ingredient.","indications":[],"catalyst":""},{"name":"Placebo of HGP0816","genericName":"Placebo of HGP0816","slug":"placebo-of-hgp0816","phase":"phase_3","mechanism":"This is a placebo control and contains no active pharmaceutical ingredient.","indications":[],"catalyst":""},{"name":"Pseudoephedrine / Levocetirizine","genericName":"Pseudoephedrine / Levocetirizine","slug":"pseudoephedrine-levocetirizine","phase":"phase_3","mechanism":"This combination drug reduces nasal congestion via pseudoephedrine (a sympathomimetic decongestant) and allergic symptoms via levocetirizine (a selective H1-receptor antagonist).","indications":["Allergic rhinitis with nasal congestion"],"catalyst":""},{"name":"RLD2001-1","genericName":"RLD2001-1","slug":"rld2001-1","phase":"phase_3","mechanism":"RLD2001-1 is a small molecule that targets the SGLT2 receptor.","indications":["Type 2 diabetes"],"catalyst":""},{"name":"RLD2001-2","genericName":"RLD2001-2","slug":"rld2001-2","phase":"phase_3","mechanism":"RLD2001-2 is a small molecule that targets the SGLT2 receptor.","indications":["Type 2 diabetes"],"catalyst":""},{"name":"RLD2002","genericName":"RLD2002","slug":"rld2002","phase":"phase_3","mechanism":"RLD2002 is a small molecule that targets the SGLT2 receptor.","indications":["Type 2 diabetes"],"catalyst":""},{"name":"RLD2106-1","genericName":"RLD2106-1","slug":"rld2106-1","phase":"phase_3","mechanism":"RLD2106-1 is a small molecule that targets the SGLT2 receptor.","indications":["Type 2 diabetes"],"catalyst":""},{"name":"RLD2204","genericName":"RLD2204","slug":"rld2204","phase":"phase_3","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"RLD2209-1","genericName":"RLD2209-1","slug":"rld2209-1","phase":"phase_3","mechanism":"RLD2209-1 is a small molecule that targets the SGLT2 receptor.","indications":["Type 2 diabetes"],"catalyst":""},{"name":"RLD2209-2","genericName":"RLD2209-2","slug":"rld2209-2","phase":"phase_3","mechanism":"RLD2209-2 is a small molecule that targets the SGLT2 receptor.","indications":["Type 2 diabetes"],"catalyst":""},{"name":"RLD2401","genericName":"RLD2401","slug":"rld2401","phase":"phase_3","mechanism":"RLD2401 is a small molecule that targets the SGLT2 receptor.","indications":["Type 2 diabetes"],"catalyst":""},{"name":"Simvast CR","genericName":"Simvast CR","slug":"simvast-cr","phase":"marketed","mechanism":"Simvastatin is an HMG-CoA reductase inhibitor that lowers cholesterol by blocking the enzyme responsible for cholesterol synthesis in the liver.","indications":["Hypercholesterolemia and dyslipidemia","Primary and secondary prevention of cardiovascular disease"],"catalyst":""},{"name":"Traclear","genericName":"Traclear","slug":"traclear","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Victoza","genericName":"Victoza","slug":"victoza","phase":"marketed","mechanism":"Glucagon-like peptide 1 receptor","indications":["Diabetes mellitus type 2","Weight loss"],"catalyst":""},{"name":"Zocor","genericName":"Zocor","slug":"zocor","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"one-way education","genericName":"one-way education","slug":"one-way-education","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"two-way education","genericName":"two-way education","slug":"two-way-education","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[{"date":"2024-02-14","type":"regulatory","headline":"Hanmi Pharmaceutical Receives FDA Approval for Generic Version of Januvia","summary":"Hanmi Pharmaceutical announced that it has received FDA approval for its generic version of sitagliptin, a diabetes treatment.","drugName":"sitagliptin","sentiment":"positive"},{"date":"2023-11-01","type":"earnings","headline":"Hanmi Pharmaceutical Reports Q3 2023 Earnings","summary":"Hanmi Pharmaceutical reported its Q3 2023 earnings, with revenue increasing by 10% year-over-year.","drugName":"","sentiment":"neutral"},{"date":"2023-08-15","type":"deal","headline":"Hanmi Pharmaceutical Partners with Chinese Company for Branded Generic Development","summary":"Hanmi Pharmaceutical announced a partnership with a Chinese company to develop and market branded generics in China.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxNa3NOUk5heHdqSF9Od1JHOGpLWEZzNnJRQm9xSU11RkxCQVMzT3RWS24tb3VNRXN5THNmZ1lCU0xUd2J5UnE0c3RnTGFjRWNScXR4MHExa0xoLXpxcVY4SnFvSHpxVzVMMGNZX0d3Ykx6TFJrVmpUWVdpWVdhVDhKS2M0QkdpT0ZuZEdqU3M3NmJvMjJSd0M1eV8tNA?oc=5","date":"2026-03-31","type":"pipeline","source":"Seoul Economic Daily","summary":"Hanmi Pharmaceutical Appoints Hwang Sang-yeon as New CEO — First Outside Chief in 53 Years - Seoul Economic Daily","headline":"Hanmi Pharmaceutical Appoints Hwang Sang-yeon as New CEO — First Outside Chief in 53 Years","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinwFBVV95cUxOSEQ2NTlmQ3pEaURtY3V1MElydjFOaTVBM01LQ0ZOMFpaRzhkb1ZqM1p6c0NqTG8tTGZvWHJFTkNaQVRqUFlPQmJJSnJxQzczQ3RFUU1QbzEyQnVYbGtvNGhSWm1xenBRSWNxRGJqakVnSDltTnA5ZkNaUE95Q3FtTk9zdkI3QWJ1MWtIOVdIdjJKdTBMcWo1bW9LVVdIRnM?oc=5","date":"2026-02-04","type":"pipeline","source":"Seoul Economic Daily","summary":"Hanmi Pharma Stock Rises as MASH Drug Listed in MSD's Key Pipeline - Seoul Economic Daily","headline":"Hanmi Pharma Stock Rises as MASH Drug Listed in MSD's Key Pipeline","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinwFBVV95cUxQX184bVRDMTRwcVJYZE43M2RmbGxqbDNudGNtb05HQUR3akFTSGV4M0E3ams3SHVoemZxWUNsd1pHUkw0aXg0cGVQemNhQXBvQzF6OWtobVBLalhqQnRiMHlwRUdLLThSeHVMTmd2TGZuSW44TFVZay0zVTRmR3FLZGI5MGtkaFd6SWxGZ0F3WkY5cEkxWUdEaUNUNTlRTUE?oc=5","date":"2026-01-23","type":"pipeline","source":"Seoul Economic Daily","summary":"Hanmi Pharmaceutical Eyes Obesity Drug Technology Export - Seoul Economic Daily","headline":"Hanmi Pharmaceutical Eyes Obesity Drug Technology Export","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMingFBVV95cUxOZUZjeTVDVjVhOF8wTDF2SkFaWi03LW1yazFldlhZaUNRU2N4OTZydEpEX3ZlQ0U1d2VoSXJTaVpvUk00WHRFMGxJVzRucmdNMGp3RGotcHM3clRXUnpBT3pmZDBxbS1BSk5PM0lXbFVVZHZpamsyQm1DY2w4MGFBdkhqQ0l0a0djV3NSRGJkVHFTRlhzVXpac2dIYnRKQQ?oc=5","date":"2026-01-21","type":"regulatory","source":"Seoul Economic Daily","summary":"Hanmi Pharmaceutical Wins Phase 3 Approval for Diabetes Drug HM11260C - Seoul Economic Daily","headline":"Hanmi Pharmaceutical Wins Phase 3 Approval for Diabetes Drug HM11260C","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMimgFBVV95cUxOTlBYQlVNMlBpMjcwLXU3LVFnZ0hRRTB1ekpOcXVid0FVd0c2NlBQbmdhWDJKNmR6NkdRY1lsLTFoVERvTFpXTXpaVjVIQUc1NEc0THZwMllTWEtPcEpDVDJFdXFVTTRNcmNLeXh4MlpNYzd1M0hMY1gzRVVIM0w4bTQ4X3Q3QTJfYU9MVU1kYlNZV3Zwc1NXRXJ3?oc=5","date":"2026-01-20","type":"trial","source":"Seoul Economic Daily","summary":"Korean Pharma Companies to Unveil Key Clinical Trial Results in 2025 - Seoul Economic Daily","headline":"Korean Pharma Companies to Unveil Key Clinical Trial Results in 2025","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxQczVxYldWSkY5SzdsclVKd0h2VTNpNW93SjBFRVNUdmVlaExuT0RRcnp1YzhmTWtjY1Z3RTAwQkxCUjdiYmhYSENjU3RIOUItcHdsUDdHMEloZXdPNFlyNkk4dm1iT3A5WlpDY2hOTTVBVk1XQ0hPSjNNdEhSU0huXzFEMnJ3YlhSRGo4NHZBMDQ4cy1GR09YS3VYZw?oc=5","date":"2026-01-13","type":"pipeline","source":"Seoul Economic Daily","summary":"Hanmi Pharma Stock Falls 10% After MSD Omits Drug From Presentation - Seoul Economic Daily","headline":"Hanmi Pharma Stock Falls 10% After MSD Omits Drug From Presentation","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipwFBVV95cUxNbUNyYUlfNkZWRXp2QWdvREdPV0dCZ3lxWnF2NUZ6TG5RMkY4b2ZkWjA0V3N0RkJkN2o3TWd3SXNwUV9SUnJDYzRGUFgzcmpIdE52VFdqS1NmRkRSZTN1SzRhQzlhbVNfdTc3LUpMQmtVSmVuSktJSlhMXzZaVEtVYjdPbVFkZjhpQlZJZnJrMTVubWVSdS02VVZzMG9wcWVSQloxbHQ5Zw?oc=5","date":"2025-12-18","type":"pipeline","source":"Seoul Economic Daily","summary":"Hanmi Pharma Price Target Raised 37% on Obesity, MASH Drug Progress - Seoul Economic Daily","headline":"Hanmi Pharma Price Target Raised 37% on Obesity, MASH Drug Progress","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiugJBVV95cUxNQVlETzFZWFN2TnItTEFrLVJ6VTFGczdTWHhhS1dtTGM5bjhKR2lQTmxMSEZRNXNGVFpqOWNfclZGTVZZb0t5Y0xFaUlFV18wZzE1LWl4RGVhV0xIUTIzVG1KTEt2U3lYYlFkVkItbGJGNVFRODRvcXpGUTYyREZXdDZfMTVDYUhFdzhQRTl2VTRDYldIZ1FtNkNOZ2NoOGNtTXdTaUxrV2ZSWmlrQjBSY3Z1Y3lpVWF3Qy1JRnBTdzMyMGRQeDVxWVZZb0o4Q1NGNUEyWm9hdUEzcGxwdGNxTW83bFVuVnR2cnhHX1Q5NFJmX2trN1JBTnRVV2FxdTJOMFFVTVVtLUY4WFMyWkZMN3RiZlBwRGNSMERfMEpLTlktNE11cTkySnBoVGRfZGhXWFktZHktdDY0Zw?oc=5","date":"2023-03-17","type":"pipeline","source":"BioSpace","summary":"Hanmi Pharmaceutical's Combination Drug for Dyslipidemia Treatment, 'Rosuzet': Confirmed Non-inferiority Efficacy and Safety Compared to Monotherapy in 'The Lancet' & 'European Heart Journal' - BioSpa","headline":"Hanmi Pharmaceutical's Combination Drug for Dyslipidemia Treatment, 'Rosuzet': Confirmed Non-inferiority Efficacy and Sa","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiVkFVX3lxTE9wRkowSVBEcXRDU3dnVU5QRDdnV2c2WnhxamZYOG05YkVIZUZnLTMtdmdyZDhfMUdpRjZlWVVDek5jQU9IMEgxRTlkSXc0TWxqX2NsdG5n?oc=5","date":"2017-05-30","type":"pipeline","source":"Yahoo Finance Australia","summary":"Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (2196.HK) stock price, news, quote and history - Yahoo Finance Australia","headline":"Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (2196.HK) stock price, news, quote and history","sentiment":"neutral"}],"patents":[{"drugName":"sitagliptin","drugSlug":"sitagliptin","patentNumber":"","type":"Patent Cliff","expiryDate":"2028-06-01","territory":"US","annualRevenue":1200000000},{"drugName":"vildagliptin","drugSlug":"vildagliptin","patentNumber":"","type":"Patent Cliff","expiryDate":"2030-06-01","territory":"EU","annualRevenue":500000000}],"drugCount":95,"phaseCounts":{"marketed":14,"phase_3":66,"phase_1":9,"phase_2":6},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Celltrion","Samsung Biologics","LG Chem"],"therapeuticFocus":["Diabetes","Obesity"],"financials":null,"yahoo":{"currentPrice":493500,"previousClose":507000,"fiftyTwoWeekHigh":647000,"fiftyTwoWeekLow":220000,"fiftyTwoWeekRange":"220000.0 - 647000.0","fiftyDayAverage":540860,"twoHundredDayAverage":409780,"beta":0.62,"enterpriseValue":6834854821888,"forwardPE":27.9,"priceToBook":0,"priceToSales":4.04,"enterpriseToRevenue":4.42,"enterpriseToEbitda":21.18,"pegRatio":0,"ebitda":322679472128,"ebitdaMargin":20.9,"freeCashflow":2284144128,"operatingCashflow":173072334848,"totalDebt":434211487744,"debtToEquity":30.5,"currentRatio":1.48,"returnOnAssets":6.7,"returnOnEquity":14.1,"analystRating":"","recommendationKey":"none","numberOfAnalysts":16,"targetMeanPrice":558750,"targetHighPrice":720000,"targetLowPrice":370000,"dividendRate":2000,"payoutRatio":0,"fiveYearAvgDividendYield":0.23,"exDividendDate":1774828800,"insiderHeldPercent":50.1,"institutionHeldPercent":20.9,"sharesOutstanding":12680214,"floatShares":6238031,"sharesShort":0,"shortRatio":0,"shortPercentOfFloat":0,"epsTrailing":0,"epsForward":0,"revenuePerShare":122046.94,"bookValue":0,"officers":[{"age":57,"name":"Mr. Jae-Hyun  Park","title":"CEO & Director"},{"age":53,"name":"Mr. Lim  Chong-Yoon","title":"President of Business Development & Executive Director"},{"age":64,"name":"Mr. Jong-Hoon  Lim","title":"CSR Executive Director"},{"age":null,"name":"Byung-hwa  Shim","title":"Chief Finance Officer"},{"age":null,"name":"Yang-Hwan  Choi","title":"Group Head of IR"},{"age":58,"name":"Mr. Jong-Soo  Woo Ph.D.","title":"Executive Director"},{"age":48,"name":"Mr. Jong-Hoon  Lim","title":"Executive Director & Management Planning /CIO"},{"age":null,"name":"Chang-Ju  Choi","title":"Vice President of Information Management Team"}],"industry":"Drug Manufacturers - Specialty & Generic","irWebsite":"","website":"https://www.hanmipharm.com","phone":"82 3 1350 5600"}}